Document is current
Any future updates will be listed below
-
Authors
Wang, Jinping
Wang, Zihan
Lan, Tianyi
Zhang, Liubo
Li, Zhenbin
Wang, Xinchang
Zou, Qinghua
Wang, Yuan
Li, Yanqi
Luo, Ruili
Zhang, Nan
Xu, Yuan
Li, Mengtao
Tao, Qingwen
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05540938 at ClinicalTrials.govDocuments that mention this clinical trial
Wangbi granule as a combination therapy to achieve clinical deep remission in rheumatoid arthritis: protocol for a multicenter, triple-blind, randomised, placebo-controlled trial
https://doi.org/10.1186/s13020-023-00728-6
-
Funding
Funding for this research was provided by:
the National High Level Hospital Clinical Research Funding (2022-NHLHCRF-LX-02-02)
- License Information
-
More Information
Article History
Received: 4 December 2022
Accepted: 14 February 2023
First Online: 28 February 2023
Declarations
:
: Ethics approval was obtained from the Clinical Research Ethics Committee of the China-Japan Friendship Hospital (No. 2022-KY-155) on 25 August 2022. The study has been registered in the ClinicalTrials Registry (ExternalRef removed) on 15 September 2022. Wangbi granule used in the trial is a marketed drug approved by China National Medical Products Administration, and its manufacturer, Good Nurse Pharmaceutical, Liaoning, China, has been notified of the trial and has provided the test medication and placebo for this trial. All participants will sign a written informed consent prior to inclusion and will be managed exclusively by a trained clinician during the study. The study will follow the Declaration of Helsink, participants can make the decision to withdraw from the trial at any time, and all data that may reveal personal privacy will be hidden.
: Not applicable.
: All authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
